SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Wound Care

PUBLISHER: Grand View Research | PRODUCT CODE: 2132387

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2132387

Wound Biologics Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Wound Biologics Market Summary

The global wound biologics market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 4.8 billion in 2033, at a CAGR of 8.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.5% in 2025. The wound biologics industry's growth is primarily driven by the rising prevalence of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, coupled with the growing global burden of diabetes and an aging population.

Increasing demand for advanced regenerative therapies, continuous innovations in bioengineered skin substitutes and growth factor-based products, and expanding clinical adoption of biologic wound care solutions to accelerate healing and reduce complications are further supporting market growth.

The increasing prevalence of chronic wounds and diabetes is a major growth driver for the wound biologics market, as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other non-healing wounds require advanced therapies that promote tissue regeneration and accelerate healing. According to the International Diabetes Federation, diabetes cases continue to rise globally, increasing the number of patients at risk of chronic wound complications. Biologic wound care products, including skin substitutes, placental tissue allografts, and extracellular matrix (ECM)-based therapies, are being adopted to improve healing outcomes, reduce infection risk, and lower amputation rates in patients with complex wounds.

The growing number of surgical procedures and traumatic injuries is a key driver of the wound biologics market, as these conditions often require advanced wound management to accelerate tissue regeneration and reduce the risk of complications, such as infection and delayed healing. Biologic wound care products, including skin substitutes, amniotic membrane allografts, and extracellular matrix (ECM)-based therapies, are increasingly being used in complex surgical wounds, orthopedic procedures, burns, and trauma cases. The rising global surgical volume and increasing incidence of road traffic accidents, sports injuries, and burn injuries continue to expand the demand for regenerative wound biologics across hospitals and trauma centers.

Global Wound Biologics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global wound biologics market report based on product, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biological Skin Substitutes
    • Allograft
    • Xenograft
    • Biosynthetic Products
  • Topical Agents
  • Collagen Dressing
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Wounds
  • Acute Wounds
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-3-68038-966-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product
    • 1.1.2. Wound Type
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Wound Biologics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rising prevalence of chronic wounds and diabetes
      • 3.2.1.2. Increasing number of surgical procedures and traumatic injuries
      • 3.2.1.3. Rising adoption of regenerative medicine and advanced wound care therapies
      • 3.2.1.4. Growing clinical evidence supporting biologic skin substitutes
      • 3.2.1.5. Increasing incidence of burns and pressure ulcers
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of biologic wound care products
      • 3.2.2.2. Limited reimbursement coverage across several countries
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Expansion of regenerative medicine and tissue engineering
      • 3.2.3.2. Development of next-generation bioengineered skin substitutes
      • 3.2.3.3. Growing adoption of placental tissue and extracellular matrix (ECM)-based products
      • 3.2.3.4. Increasing integration of ai and digital wound assessment with biologic therapies
    • 3.2.4. Market Challenge Analysis
      • 3.2.4.1. Stringent regulatory and clinical evidence requirements
      • 3.2.4.2. Pricing pressure and healthcare cost containment measures
  • 3.3. Wound Biologics Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal landscape

Chapter 4. Wound Biologics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Wound Biologics Market: Product Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Global Wound Biologics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Biological Skin Substitutes
    • 4.4.1. Biological skin substitutes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Allograft
      • 4.4.2.1. Allograft market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Xenograft
      • 4.4.3.1. Xenograft market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Biosynthetic Products
      • 4.4.4.1. Biosynthetic products market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Topical Agents
    • 4.5.1. Topical agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Collagen Dressing
    • 4.6.1. Collagen dressing market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Wound Biologics Market: Wound Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Wound Biologics Market: Wound Type Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Global Wound Biologics Market Size & Trend Analysis, by Wound Type 2021 to 2033 (USD Million)
  • 5.4. Chronic Wounds
    • 5.4.1. Chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Acute Wounds
    • 5.5.1. Acute Wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Wound Biologics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Wound Biologics Market: End use Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Global Wound Biologics Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Specialty Clinics
    • 6.5.1. Specialty Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Ambulatory Surgical Centers
    • 6.6.1. Ambulatory surgical centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Wound Biologics Market: Regional Estimates & Trend Analysis by Product, Wound Type and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size and Trend Analysis, 2021 to 2033
  • 7.3. North America
    • 7.3.1. North America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. Reimbursement scenario
      • 7.3.2.5. U.S. wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Reimbursement scenario
      • 7.3.3.5. Canada wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Reimbursement scenario
      • 7.3.4.5. Mexico wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement scenario
      • 7.4.2.5. UK wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement scenario
      • 7.4.3.5. Germany wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement scenario
      • 7.4.4.5. France wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Reimbursement scenario
      • 7.4.5.5. Italy wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Reimbursement scenario
      • 7.4.6.5. Spain wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Reimbursement scenario
      • 7.4.7.5. Sweden wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Reimbursement scenario
      • 7.4.8.5. Denmark wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Reimbursement scenario
      • 7.4.9.5. Norway wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. China wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Japan wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. India wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement scenario
      • 7.5.5.5. South Korea wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement scenario
      • 7.5.6.5. Australia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Reimbursement scenario
      • 7.5.7.5. Thailand wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Brazil wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. Argentina wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Middle East and Africa
    • 7.7.1. Middle East and Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. South Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. Saudi Arabia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. UAE wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement scenario
      • 7.7.5.5. Kuwait wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2025
  • 8.4. Company Heat Map Analysis
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research And Development
    • 8.5.6. Company Profiles
    • 8.5.7. MIMEDX Group, Inc
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Integra LifeSciences Corporation
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Organogenesis Inc.
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. BioTissue
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Skye Biologics Holdings, LLC
      • 8.5.11.1. Company overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Tissue Regenix Group
      • 8.5.12.1. Company overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. Vericel Corporation
      • 8.5.13.1. Company overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic initiatives
    • 8.5.14. Stimlabs LLC
      • 8.5.14.1. Company overview
      • 8.5.14.2. Financial performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic initiatives
    • 8.5.15. Tides Medical
      • 8.5.15.1. Company overview
      • 8.5.15.2. Financial performance
      • 8.5.15.3. Product Benchmarking
      • 8.5.15.4. Strategic initiatives
    • 8.5.16. AlloSource
      • 8.5.16.1. Company overview
      • 8.5.16.2. Financial performance
      • 8.5.16.3. Product Benchmarking
      • 8.5.16.4. Strategic initiatives
    • 8.5.17. LifeNet Health
      • 8.5.17.1. Company overview
      • 8.5.17.2. Financial performance
      • 8.5.17.3. Product Benchmarking
      • 8.5.17.4. Strategic initiatives
    • 8.5.18. MTF Biologics
      • 8.5.18.1. Company overview
      • 8.5.18.2. Financial performance
      • 8.5.18.3. Product Benchmarking
      • 8.5.18.4. Strategic initiatives
    • 8.5.19. Stryker
      • 8.5.19.1. Company overview
      • 8.5.19.2. Financial performance
      • 8.5.19.3. Product Benchmarking
      • 8.5.19.4. Strategic initiatives
    • 8.5.20. Convatec
      • 8.5.20.1. Company overview
      • 8.5.20.2. Financial performance
      • 8.5.20.3. Product Benchmarking
      • 8.5.20.4. Strategic initiatives
    • 8.5.21. Smith+Nephew
      • 8.5.21.1. Company overview
      • 8.5.21.2. Financial performance
      • 8.5.21.3. Product Benchmarking
      • 8.5.21.4. Strategic initiatives
Show more
Product Code: GVR-3-68038-966-1

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 5 North America wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 7 U.S. wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 8 U.S. wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 10 Canada wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 11 Canada wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 13 Mexico wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 14 Mexico wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 17 Europe wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 18 Europe wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Germany wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 20 Germany wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 21 Germany wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 22 UK wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 23 UK wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 24 UK wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 France wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 26 France wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 27 France wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Italy wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 29 Italy wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 30 Italy wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Spain wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 32 Spain wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 33 Spain wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Denmark wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 35 Denmark wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 36 Denmark wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Sweden wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 38 Sweden wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 39 Sweden wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Norway wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 41 Norway wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 42 Norway wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 China wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 48 China wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 49 China wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 51 Japan wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 52 Japan wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 India wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 54 India wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 55 India wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 57 South Korea wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 58 South Korea wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 60 Australia wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 61 Australia wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 63 Thailand wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 64 Thailand wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 65 Latin America wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 67 Latin America wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 68 Latin America wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Brazil wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 70 Brazil wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 71 Brazil wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 72 Argentina wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 73 Argentina wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 74 Argentina wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 MEA wound biologics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 77 MEA wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 78 MEA wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 79 South Africa wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 80 South Africa wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 81 South Africa wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 85 UAE wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 86 UAE wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 87 UAE wound biologics market, by end use, 2021 - 2033 (USD Million)
  • Table 88 Kuwait wound biologics market, by product, 2021 - 2033 (USD Million)
  • Table 89 Kuwait wound biologics market, by wound type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait wound biologics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Wound biologics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Data analysis models
  • Fig. 5 Market formulation and validation
  • Fig. 6 Data validating & publishing
  • Fig. 7 Market snapshot
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Wound biologics - market size and growth prospects (USD million)
  • Fig. 11 Wound biologics market: Industry Value Chain Analysis
  • Fig. 12 Wound biologics market: Market Dynamics
  • Fig. 13 Wound biologics market: PORTER's Analysis
  • Fig. 14 Wound biologics market: PESTEL Analysis
  • Fig. 15 Wound biologics market share by product, 2025 & 2033 (USD Million)
  • Fig. 16 Wound biologics market, by product: market share, 2023 & 2030
  • Fig. 17 Biological skin substitutes market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 18 Allograft market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 19 Xenograft market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 20 Biosynthetic products market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 21 Topical agents market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 22 Collagen dressing market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 23 Wound biologics market share by application, 2025 & 2033 (USD Million)
  • Fig. 24 Wound biologics market, by application: market share, 2025 & 2033
  • Fig. 25 Chronic wounds market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 26 Acute wounds market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 27 Wound biologics market share by end use, 2025 & 2033 (USD Million)
  • Fig. 28 Wound biologics market, by end use: market share, 2023 & 2030
  • Fig. 29 Hospitals market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 30 Specialty clinics market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 31 Ambulatory surgical centers market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 32 Others market estimates & forecasts, 2021 - 2033 (Revenue, USD Million)
  • Fig. 33 Regional marketplace: key takeaways
  • Fig. 34 North America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 US wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Canada wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Europe wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 UK wound biologics market estimates and forecasts, 2021 - 2033) (USD Million)
  • Fig. 40 Germany wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 41 France wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 42 Italy wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 43 Spain wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 44 Sweden wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 45 Denmark wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 46 Norway wound biologics market estimates and forecasts, (2021 - 2033) (USD Million)
  • Fig. 47 Asia Pacific wound biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 China wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Japan wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 India wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 South Korea wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Australia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Thailand wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Latin America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Brazil wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Argentina wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 MEA wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 South Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Saudi Arabia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 UAE wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Kuwait wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key company categorization
  • Fig. 63 Company market positioning
  • Fig. 64 Key company market share analysis, 2025
  • Fig. 65 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!